Drug Bioavailability Enhancement: Growth Opportunities
Low drug bioavailability is one of the primary concerns associated with marketed medications; in fact, various studies indicate that around 40% of available drugs are poorly bioavailable / soluble. As the drug developers shift their focus towards development of lipophilic drug compounds, the issue with aqueous solubility / drug bioavailability is likely to be increase further. It is estimated that around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low solubility / permeability. To cater to this increasing demand, several biologics contract manufacturers and technology providers have emerged in this domain.
Published Literature and the Steadily Growing IP Portfolio Validate the Underlying Importance
Drug Bioavailability enhancement technolgies are characterized by extensive R&D activity that has led to the development of a number of high value technologies and a strong intellectual property portfolio.
Several Companies have Begun to Outsource Such Services to Enhance Drug Bioavailability
Outsourcing has emerged as a popular model for improving drug bioavailability; over 150 companies offer a variety of technologies/services based on different approaches
The Current Market is a Mix of Both Well-Established and New Entrants
Entrance of new players has led to a highly fragmented market landscape; however, there are many players that have established a strong foothold over the past several years.
Large Sized Companies are Setting Benchmarks by Expanding their Service Portfolios
In fact, stakeholders have steadily added a wide range of capabilities to their service portfolios and are raising existing benchmarks
Collaborative Approach Seems to be the Way Forward
The field has witnessed significant partnering activity; in order to maintain a competitive edge, many players are rapidly expanding offerings through collaborations / acquisitions.
Marketed Drugs are Likely to Drive Short-Term Growth for These Technologies
Despite various advancements, the low solubility / permeability concerns related to certain marketed drugs and a large number of NCEs is likely to lead to an increased demand.
The Segment is Anticipated to Provide Well-Distributed Opportunity for the Stakeholders
This opportunity within the drug bioavailability enhancement market is anticipated to be well distributed in terms of drug (BCS) classes, approaches used for bioavailability enhancement and across different geographies
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com. Alternatively, you can also download the SAMPLE REPORT on drug bioavailability by Roots Analysis.
Back of the Eye Disorders: Novel Drugs and Delivery Technologies
TPD and the Rise of Kymera Therapeutics
Antibody Drug Conjugates: Riding on the Second Growth Wave
About Author
Arun_Gupta
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.